Pharmaceutical Technology14 天
IC9 CAR.19 by Bellicum Pharmaceuticals for Primary Mediastinal B-Cell Lymphoma: Likelihood ...
It is administered through intravenous route. It comprises chimeric antigen receptor (CAR) T cells which acts by targeting CD19 protein expressed on cancer cells. AP1903 is administered to activate ...
Pharmaceutical Technology16 天
IC9 CAR.19 by Bellicum Pharmaceuticals for B-Cell Acute Lymphocytic Leukemia (B-Cell Acute ...
It is administered through intravenous route. It comprises chimeric antigen receptor (CAR) T cells which acts by targeting CD19 protein expressed on cancer cells. AP1903 is administered to activate ...